Swept-source optical coherence tomography angiography for choroidal neovascularization after bevacizumab and photodynamic therapy  by Jung, Jesse J. et al.
lable at ScienceDirect
American Journal of Ophthalmology Case Reports 1 (2016) 1e4Contents lists avaiAmerican Journal of Ophthalmology Case Reports
journal homepage: http : / /www.ajocasereports .com/Case reportSwept-source optical coherence tomography angiography for
choroidal neovascularization after bevacizumab and photodynamic
therapy
Jesse J. Jung a, *, Michael H. Chen b, Patty Y. Chung a, Scott S. Lee a
a East Bay Retina Consultants, Inc., 3300 Telegraph Ave., Oakland, CA 94609, USA
b Silicon Valley Eyecare, 770 Scott Blvd., Santa Clara, CA 95050, USAa r t i c l e i n f o
Article history:
Received 6 November 2015
Received in revised form
5 January 2016
Accepted 5 January 2016
Available online 9 February 2016
Keywords:
Anti-VEGF
Bevacizumab
Neovascularization
Optical coherence tomography
Photodynamic therapy
Swept-source optical coherence
tomography angiography* Corresponding author.
E-mail address: jung.jesse@gmail.com (J.J. Jung).
http://dx.doi.org/10.1016/j.ajoc.2016.01.002
2451-9936/© 2016 The Authors. Published by Elseviera b s t r a c t
Purpose: To report the swept-source optical coherence tomography angiography (SS-OCTA) ﬁndings after
bevacizumab anti-vascular endothelial growth factor (anti-VEGF) and full-ﬂuence photodynamic therapy
(PDT) for choroidal neovascularization.
Design: Case report.
Methods: An 87-year-old, Chinese male presented with a shadow and decreased vision to 20/160 in his
left eye (OS). Clinical examination, color photographs, swept-source optical coherence tomography (SS-
OCT), wideﬁeld dye-ﬂuorescein angiography (FA) and SS-OCTA revealed an extrafoveal, subretinal
choroidal neovascularization (CNV) in the superior macula. Bevacizumab anti-VEGF and full-ﬂuence PDT
was initiated.
Results: Initial imaging with conventional color photography and FA demonstrated a classic CNV with
signiﬁcant early hyperﬂuorescence and late leakage. SS-OCT demonstrated subretinal hyperreﬂective
material, ﬂuid and hemorrhage emanating from a subretinal, type 2 neovascularization (NV). SS-OCTA
showed a mixed lesion with a type 2, subretinal component with segmentation above the retinal
pigment epithelium (RPE) and a type 1, sub-RPE component below. Treatment with anti-VEGF and PDT
led to immediate regression of the CNV. One month after treatment, SS-OCTA demonstrated signiﬁcant
resolution of the type, 2 subretinal component and decreased ﬂow and size of the type 1 sub-RPE lesion.
Conclusion: We report the ﬁrst SS-OCTA images of successfully treated extrafoveal NV after combination
PDT and ant-VEGF therapy. Early treatment of extrafoveal NV may improve our ability to treat mixed type
1 and 2 NV before these neovascular complexes mature from repetitive anti-VEGF treatment.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Choroidal neovascularization (CNV) remains one of the main
vision-threatening complications of chorioretinal diseases
including neovascular age-related macular degeneration (nAMD)
[1]. The discovery of anti-vascular endothelial growth factor
(VEGF) has revolutionized the management of nAMD and provided
unprecedented gains in visual acuity since their development.
Prior to anti-VEGF, photodynamic therapy with Verteporﬁn (PDT)
was used to treat classic CNV (Treatment of Age-Related Macular
Degeneration with Photodynamic Therapy (TAP) investigations)Inc. This is an open access article u[2], and more recently, PDT combined with anti-VEGF treatments
including bevacizumab or ranibizumab have been utilized to suc-
cessfully treat polypoidal choroidal vasculopathy (PCV) [3] and
retinal angiomatous proliferation [4]. Although combination
treatment remains effective, the immediate and long-term effects
of PDT including the extent of choroidal vascular thrombosis and
possible collateral choroidal damage has not been clearly imaged.
Conventional ﬂuorescein angiography (FA) remains essential in
the diagnosis of CNV, and the current gold standard for diagnosing
and identifying the anatomical location of CNV includes combining
optical coherence tomography (OCT) and FA together [5]. Spectral-
domain OCT (SD-OCT) is an essential tool when monitoring the
activity of nAMD at diagnosis and after intravitreal anti-VEGF
treatment, but remains limited in its ability to completely resolve
the entire extent of the neovascularization (NV) [6]. FA can clearlynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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image the true axial location, extent and size of the neo-
vascularization due to its lack of depth resolution. Another signif-
icant limitation is that FA requires intravenous injection of dye and
this invasive procedure may cause nausea, vomiting and rarely,
anaphylaxis [7].
Optical coherence tomography angiography (OCTA) is a new
imaging technique utilizing signal intensity decorrelation and/or
phase properties to non-invasively measure the ﬂow of red blood
cells [8]. En-face OCTA can generate high-resolution images of CNV
in several ophthalmic diseases including nAMD [9]. Herein, we
provide the ﬁrst swept-source OCTA (SS-OCTA) images of an
extrafoveal, mixed type 1 (sub-retinal pigment epithelium, RPE)
and type 2 (subretinal) NV membrane that was successfully treated
with combined bevacizumab and PDT. Utilizing this novel imaging
technique, we can identify and visualize each component of the NV
and demonstrate the exact effects of treatment on the vascular
network and surrounding choroidal circulation.2. Case report
An 87-year-old, Chinese male presented with a shadow and
decreased vision in his left eye (OS) for 1 day. He had previously
undergone successful cataract surgery in both eyes (OU) and had a
history of non-neovascular AMD OU. His best-corrected visual
acuity (BCVA) was 20/40 in his right eye (OD) and 20/160 OS.
Anterior examination was normal OU. Posterior evaluation OD
demonstrated few soft drusen and OS revealed an extrafoveal CNV
membrane with associated subretinal ﬂuid and hemorrhage in the
superior macula (Fig. 1). Conventional dye-FA showed a well
demarcated, early intense hyperﬂuorescence with late leakage
suspicious for a classic CNV or type 2 NV (Fig. 1). SD-OCT (Carl Zeiss
Meditec, Dublin, CA) showed a linear collection of subretinal
hyperreﬂective material (SHM) directly above the RPE line and
signiﬁcant intra- and subretinal ﬂuid with a central foveal thick-
ness (CFT) of 505-mm. En-face SS-OCTA with a central wavelength
of 1050 nm and a speed of 100,000 A-scans per second (Investi-
gational SS-OCTA Prototype; Carl Zeiss Meditec, Dublin, CA)
demonstrated a large, tangled vascular network in the subretinal
location with a connection to a deeper, sub-RPE vascular trunk
(Fig. 2). Intravitreal bevacizumabwas initiated and full-ﬂuence PDT
was performed 6 days after presentation. One month later, BCVA
OS had signiﬁcantly improved to 20/50. SD-OCT demonstrated a
CFT of 228-mm and resolution of all SHM, intra- and subretinal
ﬂuid. Repeat SS-OCTA showed regression of the type 2 componentFig. 1. Conventional imaging and ﬂuorescein angiography of an 87-year-old male with a c
ﬂuorescein angiography (FA) (Optos, Marlborough, MA, USA) (middle and right panel) of
membrane with associated subretinal ﬂuid and hemorrhage in the superior macula (left
(middle panel) with late leakage (right panel) suspicious for a classic CNV or type 2 neovaand the type 1, vascular trunk remained present with a small
decrease in size and ﬂow signal. There was minimal loss of the
surrounding choriocapillaris (Fig. 3).3. Discussion
Recently, longitudinal spectral-domain OCTA follow-up of CNV
from several diseases including nAMD showed the overall decrease
in greatest linear dimension and area after anti-VEGF treatment
[10], although type 1 NV may be more resistant [9]. In this current
case, en-face SS-OCTA using an intensity and phase-based con-
trasting microangiography algorithm-(OMAGC) with 100,000 A-
scans per second, clearly demonstrated a vascular trunk of the
extrafoveal type 1 NV and the type 2, “medusa-like” component
[9], which was leaking into the subretinal space. We elected to use
combination treatment with bevacizumab and PDT to target the
type 2 component with anti-VEGF, and PDT to decrease the size
and ﬂow and prevent maturation of the extrafoveal, type 1 lesion.
Successful combined treatment has been similarly observed in
myopic classic CNV [11] and in PCV [3]. Type 1 NV has been shown
to be quite extensive on OCTA and may represent a more chronic,
mature neovascular complex resistant to repetitive anti-VEGF
therapy [9,12]. Early treatment with combined anti-VEGF and
PDT therapy may be more effective in pruning the type 2, sub-
retinal component and controlling the type 1, sub-RPE vessels
before abnormalization therefore possibly preventing future
recurrence and need for continuous anti-VEGF injections.
The risk of chorioretinal atrophy after PDT remains a signiﬁcant
issue. It has been speculated based on conventional FA, which
showed early hypoperfusion of the choroidal circulation, that PDT
may damage the normal choroidal vascular network [11]. In this
case, we did note that there was minimal collateral damage to the
surrounding normal choriocapillaris. Evenwith presumed accurate
identiﬁcation of the NV membrane with conventional FA or
indocyanine green angiography (ICGA), the size of the treatment
area may still be overestimated due to borders of the lesion being
obscured by dye leakage. SS-OCTA allows for a clear and objective
identiﬁcation of the extent of the lesion; and future use of OCTA
when planning PDT treatment may be warranted to accurately
identify the required treatment area especially due to its increased
depth resolution compared to FA or ICGA.
Multimodal imaging with non-invasive tools such as SS-OCTA
continue to improve our ability to identify CNV and its anatomy.
The increased number of A-scans and longer wavelength with SS-
OCTA compared to SD-OCTA potentially allows for better detailedlassic, type 2 choroidal neovascularization. Color fundus photo (left panel) and dye-
the left eye demonstrated a gray, extrafoveal subretinal choroidal neovascular (CNV)
panel). Conventional FA showed a well demarcated, early intense hyperﬂuorescence
scularization.
Fig. 2. Swept-source optical coherence tomography and angiography with subretinal segmentation of the CNV before and after treatment. En-face swept-source optical coherence
tomographic angiography (Investigational SS-OCTA Prototype; Carl Zeiss Meditec, Dublin, CA) of the left macula segmented above the retinal pigment epithelium (RPE) and
included the vascularized pigment epithelial detachment (PED) before treatment (top left) demonstrated a subretinal, tangled vascular network in a “medusa-like” pattern. Note
the vascular projection artifact of the retinal vessels and capillaries at the level of the RPE. This type 2 neovascularization (NV) was clearly seen on the swept-source optical
coherence tomography (SS-OCT) with a linear collection of subretinal hyperreﬂective material (SHM) directly above the RPE and signiﬁcant intra- and subretinal ﬂuid (bottom left).
Intravitreal bevacizumab was initiated and full-ﬂuence PDT was performed 6 days after presentation and one month later, en-face SS-OCTA showed regression of the type 2 NV
component (top right), and SS-OCT demonstrated resolution of the SHM and ﬂattening of the neovascular PED (bottom right).
Fig. 3. Swept-source optical coherence tomography and angiography with sub-retinal pigment epithelium segmentation of the CNV before and after treatment. En-face swept-
source optical coherence tomography and angiography (Investigational SS-OCTA Prototype; Carl Zeiss Meditec, Dublin, CA) segmented below the retinal pigment epithelium
(RPE) of the vascularized pigment epithelial detachment showed a connection to a deeper, sub-RPE vascular trunk, which was the type 1 NV component (yellow dotted circle, top
left, bottom left). After combination treatment, there was a small decrease in size and ﬂow signal in the type 1, vascular trunk that remained in the vascularized PED (top right,
bottom right), and minimal collateral loss of the surrounding choriocapillaris after PDT treatment.
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material and depth resolution of each neovascular component.Also, increasing the number of A-scans acquired per second pro-
vides for more averaging therefore increasing the signal to noise
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single report limited to 1 month of follow-up, we demonstrate the
ﬁrst SS-OCTA images of successfully treated extrafoveal NV after
combination PDT and ant-VEGF therapy and propose that this form
of early treatment may improve our ability to treat type 1 NV before
these neovascular complexes mature and abnormalize from re-
petitive anti-VEGF treatment. Future larger and long-term studies
combining new imaging techniques such as swept-source OCTA
with treatment planning and monitoring response to therapy may
continue to improve our ability to treat CNV in nAMD.
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